Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 6/20 | 0.76 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 2/20 | 0.99 |
| ▸ | GAA | P10253 | 2/20 | 0.99 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.99 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.99 |
| ▸ | LMNA | P02545 | 1/20 | 0.99 |
| ▸ | HPGD | P15428 | 1/20 | 0.99 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.99 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.97 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.97 |
| ▸ | MMP1 | P03956 | 1/20 | 0.97 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | ACHE | P22303 | 1/20 | 0.97 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL30822976 | 1.00 | PAX8 (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL572716 | 1.00 | PAX8 (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL29359605 | 1.00 | PAX8 (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL29363805 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL4450369 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL663859 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL4033 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL5693425 | 0.99 | PAX8 (0.99) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL31175855 | 0.99 | PAX8 (0.99) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL16447653 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 616 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000666-A1 | Methods For Treating Pancreatic Cancer Using Combination Therapies | IPSEN BIOPHARM LTD. (GB) | 2026-01-01 | — | — | US | claimed |
| US-12390485-B2 | Compounds and methods for suppressing an immune response to substances containing polyethylene glycol | AAB THERAPEUTICS, LLC (US) | 2025-08-19 | — | — | US | claimed |
| US-12364691-B2 | Methods for treating pancreatic cancer using combination therapies | IPSEN BIOPHARM LTD. (GB) | 2025-07-22 | — | — | US | claimed |
| CN-119792202-A | Irinotecan hydrochloride liposome and preparation process and application thereof | 江苏长泰药业股份有限公司 | 2025-04-11 | — | — | CN | claimed |
| WO-2025032112-A1 | METHODS FOR THE TREATMENT OF TYPE 2-MEDIATED DISEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-02-13 | — | — | WO | claimed |
| EP-3363428-B1 | PERFUSION DOSAGE FORM | SUN PHARMACEUTICAL IND LTD (IN) | 2024-02-14 | — | — | EP | claimed |
| US-20240016805-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING PANCREATIC CANCER USING DEVIMISTAT | CORNERSTONE PHARMACEUTICALS INC (US) | 2024-01-18 | — | — | US | claimed |
| EP-4240344-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING PANCREATIC CANCER USING DEVIMISTAT | Cornerstone Pharmaceuticals, Inc. (US) | 2023-09-13 | — | — | EP | claimed |
| CN-116669731-A | Therapeutic methods and compositions for treating pancreatic cancer using Devista | 基石制药股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| WO-2023091964-A2 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF TUMOR METASTASIS AND HORIZONTAL GENE TRANSFER | THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE (US) | 2023-05-25 | — | — | WO | claimed |
| EP-1331005-B1 | MEDICINAL COMPOSITIONS FOR CONCOMINANT USE AS ANTICANCER ATENT | EISAI CO LTD (JP) | 2006-04-05 | — | — | EP | claimed |
| WO-2006016203-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF IRINOTECAN HYDROCHLORIDE TRIHYDRATE | SHILPA MEDICARE LIMITED (IN) | 2006-02-16 | — | — | WO | claimed |
| US-20050272755-A1 | Method for treating abnormal cell growth | PFIZER INC | 2005-12-08 | — | — | US | claimed |
| WO-2005115391-A1 | METHOD FOR TREATING ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | claimed |
| US-20050267140-A1 | Method for treating abnormal cell growth | PFIZER INC | 2005-12-01 | — | — | US | claimed |
| US-20050208146-A1 | Novel dosage and administration method for oral camptosar | PFIZER INC | 2005-09-22 | — | — | US | claimed |
| US-20040224972-A1 | Medicinal compositions for concomitant use as anticancer agent | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-11-11 | — | — | US | claimed |
| US-20040002505-A1 | Medicinal compositions for cocominant use as anticancer agent | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-01-01 | — | — | US | claimed |
| US-20030215523-A1 | Medicinal compositions for concomitant use as anticancer agent | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1331005-A1 | MEDICINAL COMPOSITIONS FOR CONCOMINANT USE AS ANTICANCER ATENT | Eisai Co., Ltd. (JP) | 2003-07-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390485-B2 | Compounds and methods for suppressing an immune response to substances containing polyethylene glycol | CD69, CCL11, CD74 | TOP1 2193/4885PAX8 2232/4885NCOA3 2312/4885 |
| US-20040224972-A1 | Medicinal compositions for concomitant use as anticancer agent | MTDH, TOP2B, TOP1 | TOP1 3/4885PAX8 2194/4885NCOA3 824/4885 |
| US-20050272755-A1 | Method for treating abnormal cell growth | CCNI, MKI67, TOP2A | TOP1 4/4885PAX8 2659/4885NCOA3 2534/4885 |
| US-20050267140-A1 | Method for treating abnormal cell growth | TYMP, MTAP, TOP1 | TOP1 3/4885PAX8 882/4885NCOA3 2700/4885 |
| US-20240016805-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING PANCREATIC CANCER USING DEVIMISTAT | RNASE1, FOLH1, PNLIP | TOP1 503/4885PAX8 3663/4885NCOA3 767/4885 |
| US-20260000666-A1 | Methods For Treating Pancreatic Cancer Using Combination Therapies | PNLIP, LIPC, PLTP | TOP1 161/4885PAX8 4664/4885NCOA3 3642/4885 |
| US-12364691-B2 | Methods for treating pancreatic cancer using combination therapies | PNLIP, RNASE1, LPXN | TOP1 171/4885PAX8 1804/4885NCOA3 1256/4885 |
| US-20030215523-A1 | Medicinal compositions for concomitant use as anticancer agent | MTDH, TOP2B, TOP1 | TOP1 3/4885PAX8 2194/4885NCOA3 824/4885 |
| US-20040002505-A1 | Medicinal compositions for cocominant use as anticancer agent | MTDH, TOP2B, CCNH | TOP1 6/4885PAX8 3475/4885NCOA3 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.